Published on in Vol 19, No 5 (2017): May

Pharma Websites and “Professionals-Only” Information: The Implications for Patient Trust and Autonomy

Pharma Websites and “Professionals-Only” Information: The Implications for Patient Trust and Autonomy

Pharma Websites and “Professionals-Only” Information: The Implications for Patient Trust and Autonomy

Original Paper

1Departments of Emergeny and Family Medicine, University of Iowa Carver College of Medicine, Iowa CIty, IA, United States

2Medical School, Technion Israel Institute of Technology, Hiafa, Israel

3Unaffiliated, Washington DC, DC, United States

Corresponding Author:

Mark Alan Graber, MSHCE, MD

Departments of Emergeny and Family Medicine

University of Iowa Carver College of Medicine

200 Hawkins Drive, 1008 RCP Iowa City, Iowa 52242

Iowa CIty, IA,

United States

Phone: 1 319 321 6572

Fax:1 319 353 7006


Background: Access to information is critical to a patient’s valid exercise of autonomy. One increasingly important source of medical information is the Internet. Individuals often turn to drug company (“pharma”) websites to look for drug information.

Objective: The objective of this study was to determine whether there is information on pharma websites that is embargoed: Is there information that is hidden from the patient unless she attests to being a health care provider? We discuss the implications of our findings for health care ethics.

Methods: We reviewed a convenience sample of 40 pharma websites for “professionals-only” areas and determined whether access to those areas was restricted, requiring attestation that the user is a health care professional in the United States.

Results: Of the 40 websites reviewed, 38 had information that was labeled for health care professionals-only. Of these, 24 required the user to certify their status as a health care provider before they were able to access this “hidden” information.

Conclusions: Many pharma websites include information in a “professionals-only” section. Of these, the majority require attestation that the user is a health care professional before they can access the information. This leaves patients with two bad choices: (1) not accessing the information or (2) lying about being a health care professional. Both of these outcomes are unacceptable. In the first instance, the patient’s access to information is limited, potentially impairing their health and their ability to make reasonable and well-informed decisions. In the second instance, they may be induced to lie in a medical setting. “Teaching” patients to lie may have adverse consequences for the provider-patient relationship.

J Med Internet Res 2017;19(5):e178



About 67% of physician office visits involve a prescription medication [1]. This rises to 80% when the visit is to an emergency department [1]. Ideally, the provider should discuss the prescriptions’ benefits and side effects with the patient. However, the scheduling realities of single visits restrict patient contact time and the information that can be presented. Unfortunately, providers often do not discuss medication side effects, and so on with patients [2,3].

Inevitably, and reasonably, patients seek out additional information. One source of this information is the Internet, including pharma websites. It is not an exaggeration to say that the use of the Internet to search for medical information is ubiquitous. In 2012, 72% of Internet users looked for medical information on the Web, and this percent has been increasing with time [4-6]. Whereas the quality of Web-based information varies greatly, unfettered access to information on the Internet is critical to patients trying to educate themselves. In order to make a truly autonomous decision, patients must have whatever information they feel is necessary. Whereas providers may not have the time to review all of the information a patient may want to know, searching the Internet is not subject to a time limitation.

The purpose of this study was to investigate a convenience selection of pharma websites in order to determine whether there is information labeled as for “professionals-only” (eg, not for patients), and what one needs to do in order to access this information. We discuss our findings within the ethical framework of Western medicine, including respect for autonomy and truth telling.

We examined a convenience sample of 40 pharma websites looking for the presence of a “professionals-only” section. Drugs websites to review were selected based on the year of approval by the Food and Drug Administration (FDA; within the past 3 years), as well as a sample of commonly prescribed medications. There was no attempt to randomize the selection. All of the researchers reviewed each site to determine whether (1) a “professionals-only” section exists, and (2) whether access to this information requires certifying that one is a health care professional.

This project did not require an institutional review board (IRB) submission because no human (or animal) subjects were involved. As noted in the University of Iowa IRB Statement of Compliance, “The University of Iowa Institutional Review Boards are duly constituted with written procedures for initial and continuing review of human subjects research” [7]. This research does not include any human subjects.

Of the 40 websites, 36 (90%) contained information or a link to information that was restricted to professionals only (Table 1). Twenty-four (67%, 24/36) of these 36 sites required an attestation that the user was a US health care professional before the information could be accessed (Table 1). Another 12 (33%, 12/36) of the 36 contained “professionals-only” information that was accessible without such an attestation. Figures 1 and 2 are screenshots that show of the type of verification required in order to access “professionals only” information. Researchers agreed on the categorization of all sites.

Figure 1. An example of a “professionals only” attestation statement from a drug company website.
View this figure
Figure 2. An example of a “professionals only” attestation statement from a drug company website.
View this figure
Table 1. Results of website evaluation.
Trade nameDrug nameWebsiteEmbargoed informationComments
AmyvidFlorbetapir F18 injectionwww.amyvid.comYes
Anoro ElliptaUmeclidinium and vilanterol inhalation powderwww.myanoro.comYes
CyramzaRamucirumab injectionwww.cyramzahcp.comYes
DuaveeConjugated estrogens or bazedoxifenewww.duavee.comOther
EntrestoSacubitril or valasartanwww.entresto.comOther
Focalin XRDexmethylphenidatewww.focalinxr.comNoc
InvokanaCanagliflozon tabletswww.invokana.comYes
HarvoniEdipasvir and sofosbuvirwww.harvoni.comYes
KadcylaAdo-trastuzumab emtansinewww.kadcyla.comYes
KynamroMipomersen sodiumwww.kynamro.comYesRequires sign-up
MyaleptMetreleptin for injectionwww.myalept.comYes
PicatoIngenol mebutatewww.picato.comYes
PomalystPomalidomide 29www.pomalyst.comYes
StribildElvitegravir, cobicistat, emtricitabine, tenofovir, and disoproxilwww.stribild.comOther
TecfideraDimethyl fumaratewww.tecidera.comYes

aYes = embargoed “professionals-only” information requiring attestation.

bOther = professionals-only information but no attestation required.

cNo = no “professionals-only” information.

Principal Findings

Restricting access to information as implemented by these websites has several implications. In the first instance, patients may not have access to desired information. Anything that limits a patient’s knowledge has the potential to adversely impact autonomy [8,9]. It can be argued that patient-oriented pharma websites contain complete information and already present all of the information that a patient needs in a useable form. Whereas it might be intuited that this solves the problem of information access, patient-oriented pharma websites may present a skewed view of drug risks and benefits and often contain advertising designed to entice the patient [10-12]. One might also argue that the lack of access to “professionals-only” information can be mitigated by the US FDA (the agency responsible for the approval and safety of drug in the United States) having made it a requirement that pharma advertising allow patient access to the package insert, including Web-based advertising [13]. However, the language of packaging information (and medical information on the Web in general) is written at a level that is often incomprehensible to the general public [14-20]. Thus, providing unfettered access to the “professionals-only” information will not in itself solve the problem of lack of accessibility; enhanced readability and a better presentation of information would generally be needed for the information consuming public. This is not an unsurmountable barrier; difficult information can be presented in a manner that is accessible to the general public [19]. We can enhance individuals’ ability to make autonomous choices by improving the quality of information presentation.

One can argue that consumers can get the same information elsewhere on the Internet (eg, wikis, sites such as This creates a fundamental dilemma, however. For patients to know what information is missing from their current knowledge base, they first need to access the “professionals-only” information. Thus, the argument that the same information is available elsewhere fails. This may be the case but the uncertainty in patients’ minds will continue.

A second, and perhaps more troubling, dilemma arises when there is “professional-only” information on pharma websites that requires an attestation as to one’s status as a health care provider. The patient can then either (1) not access the information or (2) lie about their status as a professional. Either outcome is unacceptable. Introducing lying into the therapeutic space can have adverse consequents. Requiring patients to lie in order to obtain information sets a bad precedent. If lying is tacitly accepted as part of the medical system, it has the potential to undermine one of the pillars on which medicine is built; truth telling. Worse still, the system that a patient would like to have faith in is enticing them to lie. Forcing patients to lie may challenge one’s faith in the truthfulness of other aspects of care and the medical system [21,22].

Finally, “professionals-only” information can suggest that health care professionals have some dark, mysterious secrets to be hidden from the public. Patients might legitimately wonder what it is that we health care professionals have to hide. Such concerns might further undermine trust in the medical system. Such distrust, whether generated by the perception that there is information hidden from the patient or because of the requirement to lie in the medical sphere, translates into worse patient outcomes [23,24].

It is true that patients can become overwhelmed with information. One solution is to have providers act as interpreters of information; this is the model preferred by many patients [21]. This puts the onus on providers; unfortunately, providers often do not do a particularly good job of laying out the benefits and harms of therapy either [25]. However, a provider-patient partnership with the provider interpreting information for the patient and directing the patient to reliable Web-based information can be a viable model [26].


We did not look at the content of “professionals-only” websites and compare this with the content of the patient-oriented websites. For the purposes of our study, such a comparison is a secondary consideration and would not change the study outcome; our main purpose here is to highlight the ethical issues surrounding “professionals-only” websites needing an attestation. A follow-up study could be designed to examine the issue of content. However, no matter the outcome of such an analysis, the basic dilemma remains; patients have to lie to get to “professionals-only” content or do without this information. If the content of the patient and the professional is the same, why require an attestation which may prompt the patient to lie? If the content of the professionals-only and patient-only websites are different, why are we not providing patients with the same information that we are providing to professionals (albeit presented in a manner appropriate for lay-people)?

A second weakness of our study is that we only looked at a small sample of pharma websites. It is possible, but unlikely, that many other pharma websites do not have embargoed information. Nonetheless, we have shown that there is a potential problem related to embargoed information, lying, and trust.


In conclusion, pharma websites often have a “professionals-only” section where access requires user attestation that she is a health care provider. Three problems follow. First, limited access potentially restricts patient information and therefore autonomy. Second, nonaccess may suggest that professionals have “something to hide.” Finally, such a system may “train” or induce patients to lie in other medical interactions. Distrust of the medical system may ensue.


The authors wish to thank John Stone MD, PhD for his comments on the paper.

Authors' Contributions

MAG developed the idea, collected the data, and wrote the first draft of the paper. EH and RIG collected the data and contributed to the final manuscript.

Conflicts of Interest

None declared.

  1. Centers for Disease Control and Prevention. Center for Disease Control and Prevention. Atlanta: Centers for Disease Control and Prevention; 2016 Sep 12. Therapeutic drug use   URL: [accessed 2016-12-14] [WebCite Cache]
  2. Curtis LM, Mullen RJ, Russell A, Fata A, Bailey SC, Makoul G, et al. An efficacy trial of an electronic health record-based strategy to inform patients on safe medication use: the role of written and spoken communication. Patient Educ Couns 2016 Sep;99(9):1489-1495. [CrossRef] [Medline]
  3. Ferguson S, Trupin L, Yazdany J, Yelin E, Barton J, Katz P. Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus 2016 Jan;25(1):12-17 [FREE Full text] [CrossRef] [Medline]
  4. Pew Research Center. 2013 Dec 16. Internet, science and tech, health fact sheet   URL: [accessed 2016-12-14] [WebCite Cache]
  5. Kowalski C, Kahana E, Kuhr K, Ansmann L, Pfaff H. Changes over time in the utilization of disease-related Internet information in newly diagnosed breast cancer patients 2007 to 2013. J Med Internet Res 2014 Aug 26;16(8):e195 [FREE Full text] [CrossRef] [Medline]
  6. AlGhamdi KM, Moussa NA. Internet use by the public to search for health-related information. Int J Med Inform 2012 Jun;81(6):363-373. [CrossRef] [Medline]
  7. The University of Iowa. Human Subjects Office   URL: [accessed 2017-03-11] [WebCite Cache]
  8. Beauchamp TL, Childress JF. Autonomy. In: Principles of Biomedical Ethics, 6th edition. New York: Oxford University Press; 2009:99-148.
  9. Smets EM, Deveugele M, Kripalani S, Cameron KA. New insights on information provision, decision making and patient autonomy. Patient Educ Couns 2016 Sep;99(9):1439-1440. [CrossRef] [Medline]
  10. Charbonneau DH. An analysis of benefits and risk information on pharmaceutical web sites for the treatment of menopause. Health Info Libr J 2013 Sep;30(3):212-219 [FREE Full text] [CrossRef] [Medline]
  11. Waack K, Ernst M, Graber M. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacotherapy 2004;38:26-34. [CrossRef]
  12. Graber MA, Weckmann M. Pharmaceutical company internet sites as sources of information about antidepressant medications. CNS Drugs 2002;16(6):419-423. [Medline]
  13. US Department of Health and Human Services. FDA. 1999 Aug. Consumer-Directed Broadcast Advertisements Guidance for Industry - Consumer-Directed Broadcast Advertisements   URL: [accessed 2016-12-14] [WebCite Cache]
  14. Trivedi H, Trivedi A, Hannan MF. Readability and comprehensibility of over-the-counter medication labels. Ren Fail 2014 Apr;36(3):473-477. [CrossRef] [Medline]
  15. Basara LR, Juergens JP. Patient package insert readability and design. Am Pharm 1994 Aug;NS34(8):48-53. [Medline]
  16. Wallace LS, Keenum AJ, Roskos SE, Blake GH, Colwell ST, Weiss BD. Suitability and readability of consumer medical information accompanying prescription medication samples. Patient Educ Couns 2008 Mar;70(3):420-425. [CrossRef] [Medline]
  17. Wallace LS, Roskos SE, Weiss BD. Readability characteristics of consumer medication information for asthma inhalation devices. J Asthma 2006;43(5):375-378. [CrossRef] [Medline]
  18. Graber MA, Roller CM, Kaeble B. Readability levels of patient education material on the World Wide Web. J Fam Pract 1999 Jan;48(1):58-61. [Medline]
  19. Graber MA, D'Alessandro DM, Johnson-West J. Reading level of privacy policies on Internet health Web sites. J Fam Pract 2002 Jul;51(7):642-645. [Medline]
  20. Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Aff (Millwood) 2007 May;26(3):731-740 [FREE Full text] [CrossRef] [Medline]
  21. Goold SD. Trust and the ethics of health care institutions. Hastings Cent Rep 2001;31(6):26-33. [Medline]
  22. Eyal N. Using informed consent to save trust. J Med Ethics 2014 Jul;40(7):437-444. [Medline]
  23. Tran DQ, Barry V, Antun A, Ribeiro M, Stein S, Kempton CL. Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study. Haemophilia 2016 Sep 30;23(1):98-104. [CrossRef] [Medline]
  24. Armstrong K, Rose A, Peters N, Long JA, McMurphy S, Shea JA. Distrust of the health care system and self-reported health in the United States. J Gen Intern Med 2006 Apr;21(4):292-297 [FREE Full text] [CrossRef] [Medline]
  25. Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014 Aug 12;349:g5019. [Medline]
  26. McMullan M. Patients using the internet to obtain health information: how this affects the patient-health professional relationship. Patient Educ Couns 2006 Oct;63(1-2):24-28. [CrossRef] [Medline]

US FDA: United States Food and Drug Administration

Edited by G Eysenbach; submitted 14.12.16; peer-reviewed by I Adeleke, JW Li; comments to author 11.02.17; revised version received 11.03.17; accepted 06.04.17; published 24.05.17


©Mark Alan Graber, Eliyakim Hershkop, Rachel Ilana Graber. Originally published in the Journal of Medical Internet Research (, 24.05.2017.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on, as well as this copyright and license information must be included.